Trial Profile
A phase I trial of JD5037 to treat nonalcoholic steatohepatitis (NASH)
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 20 Dec 2017
Price :
$35
*
At a glance
- Drugs CRB-4001 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions
- 20 Dec 2017 New trial record
- 14 Dec 2017 According to a Jenrin Discovery media release, the US FDA has cleared the Investigational New Drug (IND) Application for JD5037.